Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MASS-CARE

Financiado

Cerrado

Molecular Self Screening for Cervical Cancer Prevention

Cervical carcinoma is a preventable cancer caused by a persistent infection with high-risk types of human papillomavirus (hrHPV). Several western countries have implemented nation-wide screening programs based on the detection of... ver más

31/05/2017

STICHTING AMSTERDA...

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

STICHTING AMSTERDAM UMC No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2017-05-31 No tenemos la información de la convocatoria

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

STICHTING AMSTERDAM UMC

0.00€ | Lider

STICHTING VU

N.D. | Participante

Proyectos interesantes

ELEVATE

Medical Technol...

Health Informat...

4M€ Cerrado

VALID-SCREEN

Medical Technol...

Data Science

3M€ Cerrado

SixthSense

Medical Technol...

Data Science

71K€ Cerrado

MIMICS

Medical Technol...

Data Science

150K€ Cerrado

RISCC

Medical Technol...

Data Science

6M€ Cerrado

CPP2021-008440

Medical Technol...

Biomedical Imag...

534K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

STICHTING AMSTERDAM UMC No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Cervical carcinoma is a preventable cancer caused by a persistent infection with high-risk types of human papillomavirus (hrHPV). Several western countries have implemented nation-wide screening programs based on the detection of abnormal cells in cervical smears (cytology) for cervical cancer prevention. Although these programs have markedly reduced incidence in developed countries, even the most sophisticated cytology-based screening programs miss significant numbers of high-grade cervical lesions and fail to further reduce cervical cancer incidence. Besides loss to follow-up of women with abnormal cytology, the major causes underlying failure are: - Low sensitivity of the primary cytology based screening test, which is subjective, often not or poorly quality assessed (QA) and has low sensitivity for precancerous lesions - Incomplete coverage of women invited to participate in the screening program Remarkably, in developed countries with a successful nation-wide cervical screening programme 55% of all carcinomas are diagnosed in women who do not participate. Moreover, the lack of QA cytology in medium and low resource countries is one of the main reasons why incidence and mortality stay high in these countries. In recognition of these shortcomings the MASS-CARE project envisions a novel, objective, full molecular self-screening approach that enables molecular screening and triage for referral to the gynaecologist using self-collected cervico-vaginal samples as an alternative tool for cervical cancer screening. In particular, we aim to discover molecular triage markers specific for the stratification of women with hrHPV positive self-samples. The research team headed by professor Meijer has a strong track record of cutting edge translational research, has state-of-the art molecular tools in place and is equipped with unique biobanks of clinical cohorts of thousands of hrHPV positive women that are needed to successfully execute this ambitious project.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores